Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

This study tests methylnaltrexone — a drug that reverses opioid-induced constipation — to see if it can also slow the growth of head and neck squamous cell carcinoma (cancer of the mouth, throat, or larynx). The drug is given before surgery to study its effects on the tumor. **You may be eligible if...** - You are 18 or older with head and neck squamous cell carcinoma (HNSCC) - Your cancer is resectable (can be surgically removed) - You have not yet had surgery, radiation, or systemic treatment for this cancer - Your general health is adequate for surgery **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have had prior treatment for this cancer (surgery, radiation, chemo) - You have a bowel obstruction or severe gastrointestinal disease - You are pregnant or breastfeeding - You have severe kidney or liver impairment Talk to your doctor to see if this trial is right for you.